Synthesis and Anticonvulsant and Antidepressant Activity of Some 2-(6-bromo-2,3-dioxoindolin)-N-substituted Phenylacetamide Derivatives

Abstract

16 2-(6-bromo-2,3-dioxoindolin-1-yl)-N-substituted phenylacetamide derivatives were synthesized. The chemical structures of the compounds were proved by IR, ¹H-NMR, ¹³C-NMR, Mass spectrometric data and microanalyses. The antidepressant activities of the compounds were investigated by Porsolt’s behavioural despair (the forced swimming test) in mice. 2-(6-bromo-2,3-dioxoi-ndolin-1-yl)-N-(2-fluorophenyl)acetamide(4f), 2-(6-bromo-2,3-dioxoindolin-1-yl)-N-(3-chlorophenyl)acetamide(4j), 2-(6-bromo-2,3-dioxoindolin-1-yl)-N-(4-bromophenyl)acetamide(4m) reduced 54.9–44.6% duration of immobility times at 100 mg · kg⁻¹ dose level. Anticonvulsant activities were determined by substances pentylenetetrazloe(metrazol)(anti-PTZ) test, and neurotoxicities were determined by the rotarod toxicity test in mice. 12 synthesized compounds were found protective against PTZ at 100 mg ∙ kg⁻¹ dose level.

Key words

2,3-dioxoindolin - phenylacetamides - anticonvulsant activity - antidepressant activity

• References

• 1 Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity?. Psychopharmacology 1988; 94: 147-160
• 2 Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol 2004; 19: S15-S19
• 3 Williams DA, Lemke TL. Foye’s Principles of Medicinal Chemistry. 5^th ed. Lippincott Williams & Wilkins; New York: 2002. pp 384-403
• 4 Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69: 273-294
• 5 Kanner AM, Nieto JC. Depressive disorders in epilepsy. Neurology 1999; 53: S26-S32
• 6 Kühn KU, Quednow BB, Thiel M et al. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav 2003; 4: 674-679
• 7 Cramer JA, Blum D, Fanning K et al. The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav 2004; 5: 337-342
• 8 Pandeya SN, Raja AS. Synthesis of istain semicarbazones as novel anticonvulsant-role of hydrogen bonding. J Pharm Pharmaceut Sci 2002; 5: 266-271
• 9 Soyer Z, Kiliç FS, Erol K et al. Synthesis and anticonvulsant activity of some omega-(1H-imidazol-1-yl)-N-phenylacetamide and propionamide derivatives. Farmaco 2004; 59: 595-600
• 10 Sridhar SK, Pandeya SN, Stables JP et al. Anticonvulsant activity of hydrazones, Schiff and Mannich bases of isatin derivatives. Eur J Pharmaceutical Sci 2002; 16: 129-132
• 11 By Abele E, Abele R, Dzenitis O et al. Indole and isatin oximes: Synthesis, reactions, and biological activity. Chem Heterocyclic Compounds 2003; 39: 3-35
• 12 By Jensen BS, Jorgensen TD, Ahring PK et al. Use of isatin oxime derivatives as ion channel activating agents. PCT Int Appl 2000; WO 2000033834, A1 20000615.
• 13 Marvel CS, Hiers GS. Organic Syntheses Coll. 1941; 1: 327 1925; 5: 71
• 14 Gassman PG, Cue BW, Luh TY. A general method for the synthesis of isatins. J Org Chem 1977; 42: 1344-1348
• 15 Patel A, Bari S, Talele GJ et al. Sarangapani, Synthesis and antimicrobial activity of some new isatin derivatives. Iranian J Pharmaceutical Res 2006; 4: 249-254
• 16 Shah RJ, Modi NR, Patel MJ et al. Desing, synthesis and in virto antibacterial and antifungal activities of some novel spiro[azetidine-2,3´-indole]-2,4(1´H)-dione. Med Chem Res 2011; 20: 587-594
• 17 Lai YS, Ma L, Huang WX et al. Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl)phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors. Bioorg Med Chem Lett 2010; 20: 7349-7353
• 18 Modi NR, Shah RJ, Patel MJ et al. Design, synthesis, and QSAR study of novel 2-(2,3-dioxo-2,3-dihydro-1H-indol-1-yl)-N-phenylacetamide derivatives as cytotoxic agents. Med Chem Res 2011; 20: 615-625
• 19 Krall RL, Penry JK, White BG et al. Swinyard, Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978; 19: 409-428
• 20 Porter RJ, Cereghino JJ, Gladding GD et al. Antiepileptic Drug Development Program. Cleve Clin Q 1984; 51: 293-305
• 21 Porsolt RD, Bertin A, Jalfre M. Bertin A and Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-336
• 22 Porsolt RD. Antidepressants: Neurochemical Behavioral and Clinical Perspectives. In: Enna SJ, Malick JB. and Richelson. (eds.). E. Raven Press; New York: 1981: 129-139
• 23 Bourin M, Chenu F, Ripoll N et al. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 2005; 164: 266-269
• 24 Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology(Berl.) 2005; 177: 245-255
• 25 Guan LP, Zhao DH, Chang Y et al. Synthesis of 2,4-dihydroxychalcone derivatives as potential antidepressant effect. Drug Res 2013; 63: 46-51
• 26 Okada R, Negishi N, Nagaya H. The role of the nigrotegmental GABAergic pathway in the propagation of pentylenetetrazol-induced seizures. Brain Res 1989; 480: 383-387
• 27 Olsen RW. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 1981; 37: 1-13
• 28 Gale K. GABA and epilepsy: basic concepts from preclinical research. Epilepsia 1992; 33 (Suppl. 05) S3-S12